Striatal hücre tipi – spesifik moleküler imzalar distoni modelinde terapötik hedefleri ortaya çıkarır
Striatal cell-type–specific molecular signatures reveal therapeutic targets in a model of dystonia
DOI: 10.1101/2024.10.07.617010
Striatal cell-type–specific molecular signatures reveal therapeutic targets in a model of dystonia
DOI: 10.1101/2024.10.07.617010
Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians.
DOI: 10.1007/s00702-024-02838-3PMID: 39370478
Low-dose radiation research insights in experimental animals: A gateway to therapeutic implications.
DOI: 10.14202/vetworld.2024.2253-2258PMID: 39619938
Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: Focusing on Alzheimer's disease and Parkinson's disease.
DOI: 10.1016/j.ijpharm.2024.124786PMID: 39378955
MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets.
DOI: 10.1038/s41531-024-00791-2PMID: 39369002
Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program.
DOI: 10.1016/j.jcyt.2024.09.004PMID: 39425736
Palmitoylethanolamide (PEA) as a Therapeutic Agent for Neurological Pain: Mechanisms and Clinical Application
DOI: 10.22541/au.172802344.43670590/v1
Perry Disease: Current Outlook and Advances in Drug Discovery Approach to Symptomatic Treatment.
DOI: 10.3390/ijms251910652PMID: 39408987
Non-coding RNAs as therapeutic targets in Parkinson's Disease: A focus on dopamine.
DOI: 10.1016/j.prp.2024.155641PMID: 39395297
Therapeutic ultrasound: an innovative approach for targeting neurological disorders affecting the basal ganglia.
DOI: 10.3389/fnana.2024.1469250PMID: 39417047
Human olfactory neurosphere-derived cells: a unified tool for neurological disease modelling and neurotherapeutic applications.
DOI: 10.1097/js9.0000000000001460PMID: 38652180
Longitudinal trajectories of a claims-based frailty measure during adjuvant chemotherapy in women with stage I-III breast cancer.
DOI: 10.1093/oncolo/oyae092PMID: 38716777
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.